The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

North America held the largest trastuzumab biosimilars market share, and Middle East was the fastest-growing region in 2022.

The global trastuzumab biosimilars market is expected to grow from $2.64 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 27.1%. The trastuzumab biosimilars market is expected to grow from $8.86 billion in 2027 at a CAGR of 27.4%.

Major Driver In The Trastuzumab Biosimilars Market ­– Rise In The Prevalence Of Breast And Gastric Cancer
Breast cancer will afflict 2.3 million women worldwide in 2020, according to the World Health Organisation (WHO), with 685 000 deaths. Breast cancer is the most frequent cancer in women in India, accounting for 14% of all malignancies in women, according to Cancer India. As a result, the increased prevalence of breast and stomach cancer raises demand for trastuzumab biosimilars, which save money when compared to more expensive drugs, propelling the market.

View More On The Trastuzumab Biosimilars Market Report 2023 – https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Key Trastuzumab Biosimilars Market Segments
1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products
2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Recent Trastuzumab Biosimilars Market Trend – Launching New Products
The market for trastuzumab biosimilars is being shaped by major manufacturers constantly focused on releasing new products in undeveloped regions. To retain their competitive position in the market and better fulfil the demands of their customers, players competing in the trastuzumab biosimilars market are undertaking various strategic efforts such as new product development, alliances, and regional and product portfolio growth. Pfizer, for example, debuted Trazimera, a trastuzumab copycat to Herceptin, in the United States in February 2020. Trazimera is a drug that is used to treat metastatic human epidermal growth factor receptor 2 (HER2) gastric and breast cancer. Furthermore, Merck announced the launch of ONTRUZANT (trastuzumab-dttb), a Herceptin (trastuzumab) biosimilar, in April 2020. ONTRUZANT is available in the United States for about $1,325 for a single-dose vial of 150 mg and $3,709 for a multiple-dose vial of 420 mg.

Trastuzumab Biosimilars Market Prominent Players
Major players in the trastuzumab biosimilars market are Amgen Inc., Pfizer Inc., Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc.

Request A Sample Of The Global Trastuzumab Biosimilars Market Report 2023:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

The Trastuzumab Biosimilars Global Market Report 2023  provides a comprehensive overview on the trastuzumab biosimilars market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Trastuzumab biosimilar is a HER2-targeted treatment medication used to treat early and advanced HER2-positive breast cancer. Trastuzumab biosimilar is a monoclonal antibody that binds to and inactivates the human epidermal growth factor receptor 2 (HER2)/neu receptor.

View More Related Reports –
Biosimilars Global Market Report 2023
Biosimilar Monoclonal Antibodies Global Market Report 2023
Oral Biologics And Biosimilars Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model